Equities

Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.625
  • Today's Change-0.043 / -6.44%
  • Shares traded34.66k
  • 1 Year change-79.37%
  • Beta1.6407
Data delayed at least 15 minutes, as of Nov 12 2024 20:56 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast

The one analyst offering a 12 month price target expects Hepion Pharmaceuticals Inc share price to rise to 30.00 in the next year from the last price of 0.625.
High4,700.0%30.00
Med4,700.0%30.00
Low4,700.0%30.00

Earnings history & estimates in USD

On Apr 16, 2024, losses of -2.42 per share. This result exceeded the -2.63 consensus loss of the one analyst covering the company
Average growth rate-0.59%
Hepion Pharmaceuticals Inc reported annual 2023 losses of -12.32 per share on Apr 16, 2024.
Average growth rate+28.10%
More ▼

Revenue history & estimates in USD

Revenue forecasts are not available for Hepion Pharmaceuticals, Inc..
Average growth rate0.00%
Hepion Pharmaceuticals, Inc. did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.